Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation

Diffusion Pharmaceuticals Inc DFFN has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC).
In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers.
Topline results were based upon analyses of primary endpoint data, which indicate, as compared to placebo, a positive dose-response trend in TCOM readings.
Due to the small number of subjects in each cohort and the inherent variability of tcpO2 measurement, the magnitude of the effect was not statistically significant.
However, the primary endpoint data trends indicated improved peripheral oxygenation compared to placebo, with no evidence of hyperoxygenation.
The TCOM Trial was the first of three Oxygenation Trials the Company plans to conduct in 2021, including the Altitude Trial and DLCO trial.
Diffusion anticipates initiating and completing the DLCO and Altitude Trials in 2H of 2021, with topline results from each study available within two months of their respective completion.
Diffusion intends to initiate clinical studies in the identified indications during the first half of 2022.
TSC is under development to enhance oxygen diffusion to tissues with low oxygen levels (hypoxia).
Price Action: DFFN shares are down 2.57% at $0.74 during the market session on the last check Wednesday.